Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Faron Pharmaceuticals: Heights Capital reports 20.25% voting stake

Heights Capital Management submitted a voting rights notification for Faron Pharmaceuticals, showing a total voting rights stake of 20.25% as of 4 September 2026. Of this, 8.95% relates to voting rights from shares (20,394,796 direct and 25,760,000 indirect rights) and 11.30% to financial instruments in the form of two convertible bonds. In total the position represents 46,154,796 voting rights; CVI Investments is named as a shareholder. Comparative figures from an earlier notification showed a total stake of 20.72%. » Mais em de.investing.com
Faron secures funding through end of 2027 and to start BEXERA study in 2026

Faron raised about €40m through a rights issue and had cash of €32m at the end of June, which management says funds the company until the expected readout of the Phase‑IIb BEXERA data in November 2027. The first patient for the BEXERA study is still expected in 2026; recruitment is forecast to finish around August 2027. Operating loss in H1 2026 was €11.1m; the company is concentrating resources on bexmarilimab for the treatment of HR‑MDS and continues to see clinical and financing risks as well as potential dilution from new instruments. » Mais em de.investing.com
Heights Kapital Management increases stake in Faron Pharmaceuticals to 20.72%

Heights Kapital Management has raised its voting-rights stake in Faron Pharmaceuticals to 20.72%, thereby exceeding a reportable threshold. Through CVI Investments the manager holds 9.41% direct voting rights and a further 11.30% via two convertible bonds (maturities 2 August 2027 and 12 February 2028), totaling 47,211,351 voting rights. The threshold was crossed on 4 August; the issuer was informed on the same day. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, FARON PHARMACEUTICALS OY Aktie registou receitas de € 0 e um ganho líquido de -€ 8,56 mi

(EUR)	junho de 2026	YoY
Receitas	0	-
Ganho bruto	-168,93 mil	-
Ganho líquido	-8,56 mi	-
EBITDA	-10,99 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 80,94 mi
Número de ações	197,95 mi
Máximo/mínimo de 52 semanas	€ 2,45 - € 0,40
Dividendos	Não
Beta	1,12
PER (PE Ratio)	-3,20
PEG (PEG Ratio)	-1,79
P/VC (PB Ratio)	5,37
P/V (PS Ratio)	0,00

Perfil da empresa

Faron Pharmaceuticals Oy ist ein Unternehmen, das Medikamente im klinischen Stadium erforscht und entwickelt. Das Unternehmen entwickelt eine Pipeline von patentrechtlich geschützten Arzneimittelkandidaten auf der Basis von Immunmodulation für ungedeckten Bedarf, einschließlich Immunonkologie, Organschutz und regenerative Medizin. Die führenden Produktkandidaten sind Traumakine, eine intravenöse Interferon-Beta-1a-Therapie zur Behandlung von akutem Atemnotsyndrom, COVID-19, akuter Nierenschädigung, Herzschutz, Transplantation fester Organe und Ischämie-Reperfusionsschäden; und Bexmarilimab, ein neuartiger Krebsimmuntherapie-Kandidat zur Behandlung fester Tumore, nicht-kleinzelliger Lungenkarzinome und hämatologischer Malignome. Das Unternehmen entwickelt außerdem Haematokine, einen neuen chemischen AOC3-Inhibitor für die Behandlung von hämatologischen Malignomen und Knochenmarkerkrankungen. Faron Pharmaceuticals Oy wurde im Jahr 2003 gegründet und hat seinen Hauptsitz in Turku, Finnland.